Journal · News

Counterfeit Ozempic charges (Sept. 29, 2026): where brand GLP-1s in our index come from

Released: October 15, 2026 · Last reviewed: October 15, 2026

What did the FDA and the Justice Department announce?

A federal grand jury in the Middle District of Florida charged Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, with conspiracy and smuggling tied to an alleged transnational counterfeit drug scheme, according to the FDA’s press release and the Justice Department’s release, both dated September 29, 2026. The six counts cover conspiracy, smuggling, and selling or holding counterfeit drugs for sale. If convicted, each faces a maximum of 71 years in prison, the Justice Department says.

According to court documents described in both releases, the two men obtained counterfeit Ozempic “from unauthorized sources in China” and sold it to distributors in the U.S. “at deeply discounted prices.” The FDA says the fakes came with counterfeit packaging, package inserts, pen labels and needles “meant to deceive downstream customers, including pharmacies and patients.” Prosecutors also allege the sales continued after the FDA’s December 2023 seizure and public warning. FDA’s Office of Criminal Investigations is investigating.

The case is about brand-name Ozempic, not compounded semaglutide. It matters to cash-pay patients because the alleged fakes were sold into the wholesale chain, and the selling point was price.

Which counterfeit Ozempic lots has the FDA flagged before?

The FDA’s counterfeit Ozempic alert has three entries, all for Ozempic 1 mg pens. None of them names Mounjaro or Zepbound, and FDA’s counterfeit-medicine list (current as of December 8, 2025) names no other GLP-1.

In December 2023 the FDA added that the seized needles were fake, so their sterility cannot be confirmed. Novo Nordisk’s April 14, 2025 notice says a lot number alone does not prove a fake: PAR0362 is a genuine lot, and only the combination with a serial number beginning 51746517 marks a counterfeit.

Which brand GLP-1 channels in our index name the pharmacy?

Most programs in this index sell compounded drugs. A handful sell or route brand products. The table shows what each one’s own page said when we last read it, including who dispenses the medicine. A named, state-licensed dispensing pharmacy is what lets you trace a box back to an authorized distributor.

Sources: LillyDirect, Zepbound savings terms, NovoCare Pharmacy and NovoCare Wegovy pricing; LifeMD and Mochi figures from their own weight-loss pages. If a program’s page does not name its pharmacy, ask before you pay.

How big a discount should make you suspicious?

The manufacturers’ own self-pay prices set a floor for genuine brand product sold legally to cash-pay patients. The FDA lists “deep discounts or prices that seem too good to be true” as a red flag on its GLP-1 concerns page (current as of October 1, 2026). Three worked examples using the October 15 prices:

• Wegovy pen at maintenance. NovoCare charges $349 a month at 2.4 mg, or $4,188 for 12 fills. An online seller offering “Wegovy” at $150 a month is $199 below the manufacturer’s own cash price, a 57% discount ($199 / $349). No authorized channel in our index sells the pen that low after the two $199 starter fills.
• Zepbound at 10 mg. LillyDirect charges $449 a fill if each refill is bought within 45 days, or $5,388 for 12 fills. Miss the window and the 10 mg price is $699, so 12 fills at that price would be $8,388. A seller at $250 for “Zepbound 10 mg” would be $199 under Lilly’s best cash price.
• Brand through telehealth. LifeMD lists the Zepbound vial from $299 plus a $149 program fee, so the starting month is $448 before any first-month discount, which is $149 more than buying the same 2.5 mg vial from LillyDirect. The extra buys care, not a different drug.

A low price is not proof of a fake, and a normal price is not proof of a real one: the alleged counterfeits in this case were sold to distributors, so a patient could have paid an ordinary pharmacy price. That is why the dispensing pharmacy matters more than the price.

How do you check that a brand GLP-1 is genuine?

1. Fill through a state-licensed pharmacy with a prescription. FDA’s alert says patients should only get Ozempic “with a valid prescription through state-licensed pharmacies.” FDA’s BeSafeRx list adds a U.S. address and phone number and a licensed pharmacist on staff.
2. Check the website. NABP’s Safe Pharmacy page says a site ending in .pharmacy “has been accredited by NABP” and that NABP has identified more than 40,000 websites that fail its standards.
3. Check the box and pen. Compare the lot, serial number and label layout with the FDA table above. FDA’s first question is simple: does the drug or packaging look different from what you normally receive?
4. Use the manufacturer’s tools. Lilly’s counterfeit page points to its medicine verification web app and the Lilly Answers Center (1-800-545-5979). Novo Nordisk Customer Care is 1-800-727-6500.
5. Report problems. Side effects go to FDA MedWatch (1-800-FDA-1088). Suspected counterfeits go to FDA’s Office of Criminal Investigations or the FDA’s “Report a problem” page; unlawful online sellers can be reported through BeSafeRx.

Does this case change anything for compounded GLP-1s?

Not directly. Compounded tirzepatide and semaglutide are not FDA-approved, are not generic versions of Zepbound, Mounjaro, Wegovy or Ozempic, and are not counterfeits of them when made by a licensed pharmacy for a prescription. Their risk is different: quality depends on the compounding pharmacy, which is why we record which pharmacy each program names. The FDA’s September 18, 2026 warning letter to Empower Pharmacy, which said some of its compounded tirzepatide and semaglutide products “appear to be essentially copies of FDA-approved” products, shows that a named pharmacy can still draw FDA action. A name gives you something to check, not a guarantee.

What this means for you

• If you take brand Ozempic, Wegovy or Zepbound and pay cash, the manufacturers’ own channels (LillyDirect, NovoCare Pharmacy) name the pharmacy that fills your order. Telehealth programs that sell brand drugs should be able to tell you theirs.
• Treat a brand price far below $349 (Wegovy pen) or $449 (Zepbound 7.5-15 mg) as a reason to ask questions, outside the published starter offers.
• Compare programs on the same basis in our price database, and read gray-market risks and how to verify a pharmacy license before you switch to a cheaper seller.